Send to

Choose Destination
Mov Disord. 2017 Jan;32(1):108-114. doi: 10.1002/mds.26813. Epub 2016 Oct 6.

Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy.

Author information

Skåne University Hospital, Department of Neurology, Lund, Sweden.
Lund University, Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Malmö, Sweden.
Skåne University Hospital, Department of Radiation Physics, Lund, Sweden.
Skåne University Hospital, Department of Clinical Neurophysiology, Lund, Sweden.
Skåne University Hospital, Department of Clinical Physiology and Nuclear Medicine, Lund, Sweden.
Roche Pharmaceutical Research and Early Development, Neuroscience Discovery & Biomarkers, Roche Innovation Center, Basel, Switzerland.
MedTech West and the University of Gothenburg, Department of Clinical Neuroscience, Gothenburg, Sweden.
Skåne University Hospital, Memory Clinic, Malmö, Sweden.



Progressive supranuclear palsy (PSP) is difficult to diagnose accurately. The recently developed tau PET tracers may improve the diagnostic work-up of PSP.


Regional tau accumulation was studied using 18 F-AV-1451 PET in 11 patients with PSP and 11 age-matched healthy controls in the Swedish BioFinder study.


18 F-AV-1451 standard uptake volume ratios were significantly higher in the basal ganglia in PSP patients when compared with controls (globus pallidus 1.75 vs 1.50; putamen 1.51 vs 1.35). Retention in the basal ganglia was correlated with age in both groups (r = .43-.78, P < .05). In PSP, we observed a significant correlation between clinical deterioration measured with the PSP rating scale and standard uptake volume ratios in the globus pallidus (r = .74, P < .05). However, no 18 F-AV-1451 retention was observed in the cerebral cortex or white matter of either PSP patients or controls, and autoradiography did not reveal any specific binding of AV-1451 to PSP tau aggregates.


We found higher 18 F-AV-1451 retention in the basal ganglia of PSP patients when compared with healthy elderly controls, but also increases with age in both controls and patients. As a result of the overlap in retention between diagnostic groups and the age-dependent increase present also in controls, 18 F-AV-1451 PET might not reliably distinguish individual patients with PSP from controls. However, further studies are needed to evaluate whether 18 F-AV-1451 PET might be useful as a progression marker in clinical PSP trials. © The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.


Progressive supranuclear palsy; basal ganglia; positron emission tomography; tau

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center